Clinical Biopsy Articles & Analysis
7 news found
About Carcinotech Carcinotech is revolutionising cancer research by manufacturing 3D-printed micro-tumours using patient-derived biopsies, primary cells, immune cells, and cancer stem cells. Our advanced offering provides a platform for rapid, ethical, and accurate drug screening, pre-clinical, and personalised medicine testing. Carcinotech’s goal is to ...
ByCELLINK
With this partnership, the companies will offer an optimized workflow for a wide range of applications including liquid biopsy, sentinel pathogen testing, infectious disease assays, overall cancer research and drug discovery. Representative data of the liquid biopsy workflow will be presented at the American Association for Cancer Research (AACR) Annual Meeting ...
“These data show that treatment with LUPKYNIS can help patients with lupus nephritis successfully achieve UPCR treatment targets as recommended by the European Alliance of Associations for Rheumatology and the European Renal Association - a high bar to achieve and clinically meaningful,” said Dr. Anders. “A treatment response meeting these proteinuria treatment ...
Use of LUPKYNIS was safe and well tolerated in patients for up to three years of treatment, with no new safety signals In AURORA 2, long-term treatment with LUPKYNIS led to a clinically relevant preservation of kidney function in LN patients A pooled analysis from the AURA-LV and AURORA 1 studies, also presented at ERA, showed early treatment response to LUPKYNIS with ...
Tethis’ development is particularly exiting because it’s an enabling technology, one of those that can accelerate the clinical adoption of liquid biopsy testing, both for early detection of cancer and for personalized patient management. ...
Exosome Diagnostics is the world leader in developing exosomal liquid biopsy-based diagnostic assays. The EPI test is a non-invasive, urine-based genomic test that helps inform the prostate biopsy decision. ...
Clinical trial published in peer-reviewed journal demonstrates diagnostic yield from Cellvizio®significantly exceeds standard of care (84.1% vs 34.1%); use of Cellvizio drives overall change in clinical management - including need for continued surveillance or surgery - in 42.3% of cases Mauna Kea Technologies today announced a publication that demonstrates ...